1421372-76-0

Basic information

• Product Name: N-(4-(4-methylpiperazinyl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)pyrimidin-2-yl-amine
• Synonyms: N-(4-(4-methylpiperazinyl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)pyrimidin-2-yl-amine
• CAS NO: 1421372-76-0
• Molecular Weight: 473.534
• Mol File: 1421372-76-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(4-(4-methylpiperazinyl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)pyrimidin-2-yl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(4-methylpiperazinyl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)pyrimidin-2-yl-amine(1421372-76-0)
• EPA Substance Registry System: N-(4-(4-methylpiperazinyl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)pyrimidin-2-yl-amine(1421372-76-0)

Safety Data

• Hazardous Substances Data: 1421372-76-0(Hazardous Substances Data)

Upstream product

• 603-76-9 1-methylindole 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 120-72-9 indole 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 109-01-3 1-methyl-piperazine 
• 1421372-94-2 N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 

Downstream Products

• 1421372-75-9 6-methoxy-N¹-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)benzene-1,3-diamine 
• 1421373-71-8 EB₁₀₄ 

Relevant articles and documents

P-phenylenediamine LSD1 inhibitor and preparation method thereof

Disclosed are a p-phenylenediamine derivative as represented by general formula I, a pharmaceutically acceptable salt, and a stereoisomer thereof. The p-phenylenediamine derivative as represented by general formula I, the pharmaceutically acceptable salt thereof and the stereoisomer thereof can be used alone or in combination as lysine-specific demethylase-1 (LSD1) inhibitors.

Design, synthesis and structure-activity relationship studies of 4-indole-2-arylaminopyrimidine derivatives as anti-inflammatory agents for acute lung injury

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS), a clinically high mortality disease, has not been effectively treated till now, and the development of anti-acute lung injury drugs is imminent. Acute lung injury was efficiently treated by inhibiting the cascade of inflammation, and reducing the inflammatory response in the lung. A series of novel compounds with highly efficient inhibiting the expression of inflammatory factors were designed by using 4-indolyl-2-aminopyrimidine as the core skeleton. Totally eleven 4-indolyl-2-arylaminopyrimidine derivatives were designed and synthesized. As well, the related anti-ALI activity of these compounds was evaluated. Compounds 6c and 6h showed a superior activity among these compounds, and the inhibition rate of IL-6 and IL-8 release ranged from 62% to 77%, and from 65% to 72%, respectively. Furthermore, most of compounds had no significant cytotoxicity in vitro. The infiltration of inflammatory cells into lung tissue significantly reduced by using compound 6h (20 mg/kg) in the ALI mice model, which achieved the effect of protecting lung tissue and improving ALI. In addition, the inflammatory response was inhibited by using compound 6h through inhibiting phosphorylation of p-38 and ERK in MAPK signaling pathway, and resulted in protective effect on ALI. These data indicated that compound 6h showed good anti-inflammatory activity in vitro and in vivo, which was expected to become a leading compound for the treatment of ALI.

4-indole-2-arylaminopyrimidine compound and application thereof in inflammation treatment

The invention belongs to the field of medicinal chemistry, and particularly discloses an N-(4-(1-methyl-1H-indole-3-yl) pyrimidine-2-yl)benzene-1,3-diamine analogue shown as the following formula (I),in the formula, R1 is selected from H, halogen or C1-C5 alkoxy, R2 is selected from H, halogen a C1-C12 chain alkyl substituted nitrogen-containing group, a C3-C6 cyclic group substituted nitrogen-containing group, a five-membered nitrogen-containing heterocyclic ring, a six-membered nitrogen-containing heterocyclic ring or a seven-membered nitrogen-containing heterocyclic ring. The invention further discloses an application of the compound shown in the formula (I) in preparation of drugs for inflammation-related diseases, and pharmacological results show that the N-(4-(1-methyl-1H-indol-3-yl)pyrimidine-2-yl)benzene-1,3-diamine analogue can effectively inhibit release of IL-6 and IL-8 inflammatory factors and has good anti-inflammatory activity.